FDA expanded the approved use of abiraterone acetate (Zytiga, Jannsen Bioech) to treat men with late-stage castration-resistant prostate cancer prior to receiving chemotherapy.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

FDA expands Zytiga's use for late-stage prostate cancer

Newsletter